Research on Omitting Sentinel Lymph Node Biopsy after Neoadjuvant Therapy in cN1 Breast Cancer Patients
Cancer Medicine · 2026-04 · 15 (4)
DOI: 10.1002/cam4.71845 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 21.04.2026. Verfasst von Jiabei Shang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, The Affiliated Hospital of Southwest Medical University, Luzhou, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Sentinel Lymph Node Biopsy, Neoadjuvant Therapy. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Doctoral Research Initiation Fund of Affiliated Hospital of Southwest Medical University, Luzhou Multidisciplinary Precision Diagnosis and Treatment Quality Control Center for Breast Cancer, 2024, Beijing Vlove Charity Foundation.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Some patients with clinically node‐positive (cN1) breast cancer (BC) can achieve axillary pathological complete response (apCR) in axillary lymph nodes (ALNs) after neoadjuvant therapy (NAT). This study investigated predictors of post‐NAT pathological node‐negative (ypN0) status in cN1 breast cancer patients to identify candidates for omitting sentinel lymph node biopsy (SLNB).
Methods
This study included patients diagnosed with stage cT1‐4 N1 breast cancer who received NAT followed by breast surgery and axillary lymph node dissection (ALND) at the Breast Surgery Department of the Affiliated Hospital of Southwest Medical University between January 2020 and April 2025. Univariate and multivariate logistic regression analyses were conducted to identify factors predictive of ypN0 status across different molecular subtypes.
Results
This study enrolled 357 patients: 147 achieved ycN0 after NAT, while 210 remained ycN1. Multivariate analysis revealed: in ycN0 patients, only breast pathological complete response(bpCR) predicted ypN0 (OR: 0.151, 95% CI: 0.055–0.419); in ycN1 patients, both bpCR (OR: 0.038, 95% CI: 0.015–0.098) and MRI radiological complete response of lymph nodes (MRI‐rCR(LN))(OR: 0.36, 95% CI: 0.156–0.832) were significant predictors. Univariate analysis identified ten ypN0‐associated factors including bpCR. Luminal B HER2+ subtypes showed significantly higher ypN0 rates versus other subtypes.
Conclusions
Specific predictors (notably bpCR and MRI‐rCR(LN)) are strongly associated with ypN0 in cN1 BC post‐NAT, with Luminal B HER2+ patients demonstrating superior response rates. These findings support selective SLNB omission in cN1 patients achieving these key response markers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Breast Surgery, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
- Medical Cosmetology Center, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
- Southwest Medical University, Luzhou, China.
- Department of Breast, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, China.
- Department of Breast and Thyroid Surgery, Suining Central Hospital, Suining, China.
- Radiology Department, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
ORCID-Profile: Jiabei Shang, Jianzhe Chen, Xinrui Wu
Förderung
- Doctoral Research Initiation Fund of Affiliated Hospital of Southwest Medical University
- Luzhou Multidisciplinary Precision Diagnosis and Treatment Quality Control Center for Breast Cancer, 2024
- Beijing Vlove Charity Foundation
- sichuan medical science and technology innovation research association
Zitieren
APA
Shang, J., Chen, J., Zheng, R., Huang, Z., Wu, X., Min, J., Chen, M., Quan, Y., Wu, B., Zuo, H., Fu, H., Wan, Y., Bai, J., & Pan, G. (2026). Research on Omitting Sentinel Lymph Node Biopsy after Neoadjuvant Therapy in cN1 Breast Cancer Patients. Cancer Medicine, 15(4). https://doi.org/10.1002/cam4.71845
Vancouver
Shang J, Chen J, Zheng R, Huang Z, Wu X, Min J, et al. Research on Omitting Sentinel Lymph Node Biopsy after Neoadjuvant Therapy in cN1 Breast Cancer Patients. Cancer Medicine. 2026;15(4). doi:10.1002/cam4.71845
BibTeX
@article{Shang2026,
author = {Shang, Jiabei and Chen, Jianzhe and Zheng, Ruchun and Huang, Zhaoyu and Wu, Xinrui and Min, Jie and Chen, Maoshan and Quan, Yi and Wu, Bin and Zuo, Huaiquan and Fu, Hua and Wan, Yuepin and Bai, Jiao and Pan, Guangrui},
title = {Research on Omitting Sentinel Lymph Node Biopsy after Neoadjuvant Therapy in cN1 Breast Cancer Patients},
journal = {Cancer Medicine},
year = {2026},
volume = {15},
number = {4},
doi = {10.1002/cam4.71845}
}
EUVIMED